New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve

PR Newswire03-31

TRILUMINATE™ Pivotal data presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in Circulation show the Abbott TriClip system reduces heart ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2523447079?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-31 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2523447079","market":"nz","top_or_hot":-1,"title":"New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve","media":"PR Newswire","content":"<div>\n<p>TRILUMINATE™ Pivotal data presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in Circulation show the Abbott TriClip system reduces heart ...</p>\n\n<a href=\"https://finance.yahoo.com/news/breaking-data-reinforce-benefits-abbotts-130000376.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Late-Breaking Data Reinforce Benefits of Abbott's TriClip™ for People With Leaky Tricuspid Heart Valve\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-31 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/breaking-data-reinforce-benefits-abbotts-130000376.html><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TRILUMINATE™ Pivotal data presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in Circulation show the Abbott TriClip system reduces heart ...</p>\n\n<a href=\"https://finance.yahoo.com/news/breaking-data-reinforce-benefits-abbotts-130000376.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1721429741.USD","symbol_name":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","start_time":0,"source_url":"https://finance.yahoo.com/news/breaking-data-reinforce-benefits-abbotts-130000376.html","article_id":"2523447079","we_media_id":null,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/breaking-data-reinforce-benefits-abbotts-130000376.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2523447079","pubTimestamp":1743426000,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"TRILUMINATE Pivotal data presented at the American College of Cardiology's Annual Scientific Session  and simultaneously published in Circulation show the Abbott TriClip system reduces heart failure hospitalizations. The latest results highlight significant improvements in tricuspid regurgitation and quality of life through two years. TR can reduce the amount of blood being pumped through the body and force the heart to work harder than it should, causing debilitating symptoms such as fatigue and shortness of breath.When left untreated, TR can lead to atrial fibrillation, heart failure and, ultimately, death. For those who are not good candidates for surgery and continue to have symptoms or persistent TR despite treatment with medical therapy, TriClip represents a needed option that can improve a person's quality-of-life and keep them out of the hospital.Significant, sustained reduction in TR grade. Significant reduction in TR to moderate or less  was achieved in 84% of patients with t","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK4581":"高盛持仓","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","BK4504":"桥水持仓","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","SG9999002224.SGD":"Allianz Global High Payout SGD","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4212":"包装食品与肉类","BK4592":"伊斯兰概念","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","BK4585":"ETF&股票定投概念","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4566":"资本集团","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","BK4082":"医疗保健设备","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","ABT":"雅培","BK4568":"美国抗疫概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4588":"碎股","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","TR":"Tootsie Roll Industries Inc","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC"},"translate_title":"新的最新数据强化了雅培TriClip™对三尖瓣渗漏患者的益处","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":1,"TR":1},"content_text":"TRILUMINATE™ Pivotal data presented at the American College of Cardiology's Annual Scientific Session (ACC.25) and simultaneously published in Circulation show the Abbott TriClip system reduces heart failure hospitalizations\nThe latest results highlight significant improvements in tricuspid regurgitation and quality of life through two years\n\nABBOTT PARK, Ill., March 31, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from its TRILUMINATE™ Pivotal trial that show the TriClip™ transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR), or a leaky heart valve, offers substantial and sustained improvements in the severity of TR after two years. The results also demonstrate the TriClip device significantly reduced the rate of hospitalizations due to heart failure compared to medical therapy, while offering long-term quality-of-life benefits for patients.\nTR can reduce the amount of blood being pumped through the body and force the heart to work harder than it should, causing debilitating symptoms such as fatigue and shortness of breath. When left untreated, TR can lead to atrial fibrillation, heart failure and, ultimately, death. For those who are not good candidates for surgery and continue to have symptoms or persistent TR despite treatment with medical therapy, TriClip represents a needed option that can improve a person's quality-of-life and keep them out of the hospital.\nThe data were presented at the American College of Cardiology's Annual Scientific Session (ACC.25) held in Chicago (March 29-31, 2025) and simultaneously published in Circulation.\nSustained Benefits for Patients With Severe Leaky Heart ValveAfter two years, the TRILUMINATE Pivotal study found TriClip continued to demonstrate superiority compared to medical therapy while meeting the secondary endpoints of recurrent heart failure hospitalizations (HFH) and freedom from all-cause mortality, tricuspid valve surgery and tricuspid valve intervention. After the first year of the trial, patients in the control group (medical therapy) were allowed to cross over to receive TriClip therapy, and more than half (142 of 241 eligible patients) received TriClip.\nAdditional positive two-year findings from the TRILUMINATE Pivotal trial include:\n\nSignificant reduction in HFH. The rate of HFH was significantly lower in the treatment group compared to the control group (0.19 vs. 0.26 events/patient-year, p=0.02). Also, control patients who switched to TriClip treatment had a drop in HFH after receiving the device (0.5 vs. 0.35 events/patient-year).\nSignificant, sustained reduction in TR grade. Significant reduction in TR to moderate or less (grade ≤ 2) was achieved in 84% of patients with the device vs. 21% of patients in the control group. Similar improvements were seen in the control group patients who crossed over, with 81% of patients achieving moderate or less TR at 30 days after receiving TriClip compared to 3% prior to crossing over.\nSignificant, sustained improvement in quality of life. Patients who received TriClip achieved more than a 15-point improvement on average in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score (a self-assessment of social abilities, symptoms and quality of life) throughout follow-up. Patients in the crossover group achieved similar improvements in KCCQ score (+13 points on average) once implanted with TriClip.\n\n\"With the TRILUMINATE Pivotal two-year results, tricuspid transcatheter edge-to-edge repair with the TriClip device for severe, symptomatic tricuspid regurgitation reduced heart failure hospitalizations compared to the control group. Improvements in tricuspid regurgitation severity and quality of life were sustained through two years,\" said Saibal Kar, M.D., Los Robles Regional Medical Center in Thousand Oaks, California. \"When we combine this with the consistent quality-of-life improvements people who receive the TriClip system experience, it's clear that the benefits for patients with TR are very meaningful and TriClip offers a safe, effective and sustainable way to repair the tricuspid valve.\"\n\"These new data reinforce the critical role TriClip plays in helping people with tricuspid regurgitation live the life they want while reducing the risk of hospitalization,\" said Sandra Lesenfants, senior vice president of Abbott's structural heart business. \"Patients battling TR face serious challenges, including increased risk of heart failure, as a result of this debilitating condition. Unfortunately, many are not eligible for open-heart surgery and had limited treatment options prior to the approval of TriClip, a significant advancement that allows patients to reclaim their lives.\"\nAbout the Abbott TRILUMINATE Pivotal TrialThe TRILUMINATE Pivotal trial is the first randomized, controlled clinical study to evaluate the safety and effectiveness of transcatheter repair with the TriClip system compared to medical therapy alone in people with severe TR. The primary endpoint was a composite of all-cause mortality or tricuspid valve surgery, heart failure hospitalizations, and quality-of-life improvement measured by the KCCQ score.  \nTriClip is approved for use in more than 50 countries, including in the U.S., Europe and Canada.\nFor U.S. important safety information on TriClip, visit https://abbo.tt/TriClip_ISI. \nAbout AbbottAbbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.\nConnect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. \n View original content:https://www.prnewswire.com/news-releases/new-late-breaking-data-reinforce-benefits-of-abbotts-triclip-for-people-with-leaky-tricuspid-heart-valve-302413554.html\nSOURCE Abbott","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.0","shortVersion":"4.33.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2523447079"}